Skip Navigation

Japanese Journal of Clinical Oncology 2005 35(2):88-89; doi:10.1093/jjco/hyi025
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Komatsu, Y.
Right arrow Articles by Asaka, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Komatsu, Y.
Right arrow Articles by Asaka, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2005 Foundation for Promotion of Cancer Research

Clinical Trial Note

Phase II Study of Oral S-1 Plus Irinotecan in Patients with Advanced Colorectal Cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302

Yoshito Komatsu1,2, Satoshi Yuuki1, Nozomu Fuse1, Masaaki Takei1, Takashi Kato1, Takuto Miyagishima1, Mineo Kudo1, Yasuyuki Kunieda1, Miki Tateyama1, Osamu Wakahama1, Takashi Meguro1, Hiroko Ohizumi1, Maso Watanabe1, Hirotoshi Akita2, Yu Sakata3 and Masahiro Asaka1

1 Department of Gastroenterology and 2 Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo and 3 Misawa City Hospital, Misawa, Aomori, Japan

For reprints and all correspondence: Yoshito Komatsu, Department of Gastroenterology, Hokkaido University School of Medicine, North 15, West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan. Email: ykomatsu{at}med.hokudai.ac.jp

Received December 12, 2004; accepted December 23, 2004

We have previously reported on phase I/II studies of irinotecan plus S-1 therapy for advanced gastric cancer. Based on the safety and efficacy data that were obtained, this phase II study was planned to assess the efficacy of irinotecan plus S-1 for patients with advanced colorectral cancer. A total of 40 patients are enrolled at 13 medical institutions. The objective of this study was to establish a useful chemotherapy regimen for an out-patient setting.

Key Words: S-1 • irinotecan • phase II study • colorectal cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.